Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Foetal exposure to acetaminophen tied to increased risk for ADHD, autism

Elaine Soliven
01 Dec 2019

Foetal acetaminophen exposure may increase a child’s risk for attentiondeficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), according to a new study.

Researchers analysed data from 996 mother-infant dyads, which were a subset of the Boston Birth Cohort, from October 1998 and June 2018 and measured three cord acetaminophen metabolites — unchanged acetaminophen, acetaminophen glucuronide, and 3-[N-acetyl-L-cystein-S-yl]-acetaminophen — in archived cord plasma samples collected at birth.

Included in the final sample were 257 children (25.8 percent) with ADHD only, 66 (6.6 percent) with ASD only, 42 (4.2 percent) with both ADHD and ASD, 304 (30.5 percent) with other developmental disabilities, and 327 (32.8 percent) who were neurotypical. Unchanged acetaminophen levels were detected in all cord plasma samples. [JAMA Psychiatry 2019;doi:10.1001/jamapsychiatry.2019.3259]

Being in the second and third tertiles of cord acetaminophen burden was associated with higher odds of ADHD diagnosis (odds ratio [OR] for second tertile, 2.26, 95 percent confidence interval [CI], 1.4–3.69; OR for third tertile, 2.86, 95 percent CI, 1.77–4.67), and ASD diagnosis (OR for second tertile, 2.14, 95 percent CI, 0.93–5.13 and OR for third tertile, 3.62, 95 percent CI, 1.62–8.6).

There were consistent associations between acetaminophen burden and ADHD and acetaminophen burden and ASD which persisted across strata of potential confounders, such as child age and sex, preterm birth, substance use, and maternal indication.

“We identified a significant positive association between cord plasma acetaminophen metabolites and the risk for ADHD diagnosis and the risk for ASD in childhood,” said Yuelong Ji, a post-doctoral fellow at Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, US. “The significant positive associations between cord acetaminophen and ADHD and the cord acetaminophen and ASD were observed across strata of pertinent covariates, including maternal fever during pregnancy, which is an indicator for acetaminophen use”.

“Our findings, the first to investigate associations between neurodevelopmental disabilities with adjustments for potential covariates and cord plasma metabolites of acetaminophen, support previous studies regarding the association between prenatal and perinatal acetaminophen exposure and childhood neurodevelopmental risk,” said the researchers.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]